{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:38:28Z","timestamp":1772771908309,"version":"3.50.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Italia and Bristol Myers Squibb Italia"},{"name":"Scuola Superiore Sant'Anna within the CRUI-CARE Agreement"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40261-021-01002-z","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T19:09:25Z","timestamp":1613675365000},"page":"255-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available \u201cReal-World\u201d Evidence: The Italian National Health System Perspective"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9948-0301","authenticated-orcid":false,"given":"Valentina","family":"Lorenzoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Pirri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Turchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"8","key":"1002_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837\u201347.","journal-title":"Circulation."},{"issue":"36","key":"1002_CR2","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC\/EACTS Guidelines for the management of valvular heart disease: the Task Force for the Management of Valvular Heart Disease. Eur Heart J. 2017;38(36):2739\u201386.","journal-title":"Eur Heart J."},{"issue":"11","key":"1002_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","volume":"11","author":"F Rahman","year":"2014","unstructured":"Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11):639\u201354.","journal-title":"Nat Rev Cardiol."},{"issue":"1","key":"1002_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/europace\/eut263","volume":"16","author":"P Kirchhof","year":"2014","unstructured":"Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6\u201314.","journal-title":"Europace."},{"issue":"6","key":"1002_CR5","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1160\/TH11-02-0070","volume":"105","author":"P Kirchhof","year":"2011","unstructured":"Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A, et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost. 2011;105(6):1010\u201323.","journal-title":"Thromb Haemost."},{"issue":"47","key":"1002_CR6","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1093\/eurheartj\/ehu374","volume":"35","author":"GYH Lip","year":"2014","unstructured":"Lip GYH, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J. 2014;35(47):3365\u201376.","journal-title":"Eur Heart J."},{"key":"1002_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15829\/1560-4071-2017-7-7-86","volume":"147","author":"P Kirchhof","year":"2017","unstructured":"Kirchhof P, Benussi S, Zamorano JL, Aboyans V, Achenbach S, Agewall S, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Russ J Cardiol. 2017;147:7\u201386.","journal-title":"Russ J Cardiol."},{"issue":"4","key":"1002_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1538-7836.2004.00659.x","volume":"2","author":"APA Gadisseur","year":"2004","unstructured":"Gadisseur APA, Kaptein AA, Breukink-Engbers WGM, Van Der Meer FJM, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost. 2004;2(4):584\u201391.","journal-title":"J Thromb Haemost."},{"key":"1002_CR9","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2147\/TCRM.S84210","volume":"11","author":"YH Mekaj","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967\u201377.","journal-title":"Ther Clin Risk Manag"},{"key":"1002_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1160\/TH14-03-0228","volume":"111","author":"S Husted","year":"2014","unstructured":"Husted S, de Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost. 2014;111:781\u20132.","journal-title":"Thromb Haemost"},{"key":"1002_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med."},{"key":"1002_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med."},{"key":"1002_CR13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"issue":"12","key":"1002_CR14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med."},{"issue":"6","key":"1002_CR15","doi-asserted-by":"publisher","first-page":"e008034","DOI":"10.1161\/JAHA.117.008034","volume":"7","author":"F Mayer","year":"2018","unstructured":"Mayer F, Kirchmayer U, Coletta P, Agabiti N, Belleudi V, Cappai G, et al. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: pilot implementation of a near-real-time monitoring program in Italy. J Am Heart Assoc. 2018;7(6):e008034.","journal-title":"J Am Heart Assoc."},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1160\/TH15-06-0453","volume":"114","author":"TC Villines","year":"2015","unstructured":"Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114:1290\u20138.","journal-title":"Thromb Haemost"},{"key":"1002_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1160\/TH16-08-0658","volume":"116","author":"B Freedman","year":"2016","unstructured":"Freedman B, Lip GYH. \u201cUnreal world\u201d or \u201creal world\u201d data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost. 2016;116:587\u20139.","journal-title":"Thromb Haemost"},{"issue":"2","key":"1002_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10198-019-01123-5","volume":"21","author":"G de Pouvourville","year":"2020","unstructured":"de Pouvourville G, Blin P, Karam P. The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France. Eur J Health Econ. 2020;21(2):235\u201349.","journal-title":"Eur J Health Econ."},{"issue":"3","key":"1002_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40273-017-0596-z","volume":"36","author":"A Makady","year":"2018","unstructured":"Makady A, van Veelen A, Jonsson P, Moseley O, D\u2019Andon A, de Boer A, et al. Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics. 2018;36(3):359\u201368.","journal-title":"Pharmacoeconomics."},{"key":"1002_CR20","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","volume":"359","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.","journal-title":"BMJ."},{"issue":"10","key":"1002_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1\u201334.","journal-title":"J Clin Epidemiol."},{"key":"1002_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2288-10-54","volume":"10","author":"BS Woods","year":"2010","unstructured":"Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10:54.","journal-title":"BMC Med Res Methodol."},{"key":"1002_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21090","volume":"21","author":"JA Sterne","year":"2017","unstructured":"Sterne JA, Bodalia PN, Bryden PA, Davies PA, Lopez-Lopez JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21:1\u2013386.","journal-title":"Health Technol Assess"},{"issue":"2","key":"1002_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1258\/1355819011927288","volume":"6","author":"A Robinson","year":"2001","unstructured":"Robinson A, Thomson R, Parkin D, Sudlow M, Eccles M. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy. 2001;6(2):92\u20138.","journal-title":"J Health Serv Res Policy."},{"issue":"8","key":"1002_CR25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/jech.57.8.622","volume":"57","author":"EA Lacey","year":"2003","unstructured":"Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health. 2003;57(8):622\u20137.","journal-title":"J Epidemiol Community Health."},{"issue":"1","key":"1002_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/jamia.1997.0040049","volume":"4","author":"LA Lenert","year":"1997","unstructured":"Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Informatics Assoc. 1997;4(1):49\u201356.","journal-title":"J Am Med Informatics Assoc."},{"key":"1002_CR27","unstructured":"Elenchi farmaci di classe A e H | Agenzia Italiana del Farmaco [Internet]. [cited 2020 Jun 14]. https:\/\/www.aifa.gov.it\/liste-farmaci-a-h."},{"key":"1002_CR28","unstructured":"Gazzetta Ufficiale [Internet]. [cited 2020 Jun 14]. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2019\/03\/06\/19A01576\/sg."},{"key":"1002_CR29","unstructured":"Gazzetta Ufficiale [Internet]. [cited 2020 Jun 14]. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2019\/03\/06\/19A01575\/sg."},{"key":"1002_CR30","unstructured":"Gazzetta Ufficiale [Internet]. [cited 2020 Jun 14]. https:\/\/www.gazzettaufficiale.it\/eli\/id\/2019\/03\/06\/19A01565\/sg."},{"issue":"1S","key":"1002_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7175\/fe.v15i1s.972","volume":"15","author":"L Pradelli","year":"2014","unstructured":"Pradelli L, Calandriello M, Di Virgilio R, Bellone M, Tubaro M. The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban. Farmeconomia Heal Econ Ther pathways. 2014;15(1S):3\u20134.","journal-title":"Farmeconomia Heal Econ Ther pathways."},{"issue":"3","key":"1002_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7175\/fe.v13i3.268","volume":"13","author":"F Mennini","year":"2012","unstructured":"Mennini F, Russo S, Marcellusi A. Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy. Farmeconomia Heal Econ Ther Pathways. 2012;13(3):121\u201331.","journal-title":"Farmeconomia Heal Econ Ther Pathways."},{"key":"1002_CR33","unstructured":"Italian Ministry of Health. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Gazz Uff Ser Gen. 2013."},{"key":"1002_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/CIA.S36828","volume":"7","author":"P Piscitelli","year":"2012","unstructured":"Piscitelli P, Iolascon G, Argentiero A, Chitano G, Neglia C, Marcucci G, et al. Incidence and costs of hip fractures vs strokes and acute myocardial infarction in Italy: comparative analysis based on national hospitalization records. Clin Interv Aging. 2012;7:575\u201383.","journal-title":"Clin Interv Aging."},{"key":"1002_CR35","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.amjmed.2014.07.023","volume":"127","author":"TB Larsen","year":"2014","unstructured":"Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjoth F, Lane DA, Lip GYH. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med. 2014;127:1172-1178.e5.","journal-title":"Am J Med"},{"issue":"3","key":"1002_CR36","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/europace\/euw416","volume":"20","author":"T Forslund","year":"2018","unstructured":"Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-Vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2018;20(3):420\u20138.","journal-title":"Europace."},{"issue":"10","key":"1002_CR37","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1080\/03007995.2017.1334638","volume":"33","author":"S Deitelzweig","year":"2017","unstructured":"Deitelzweig S, Luo X, Gupta K, Trocio J, Mardekian J, Curtice T, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017;33(10):1745\u201354.","journal-title":"Curr Med Res Opin."},{"key":"1002_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/STROKEAHA.116.015150","volume":"48","author":"I Hernandez","year":"2017","unstructured":"Hernandez I, Zhang Y, Brooks MM, Chin PKL, Saba S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke. 2017;48:159\u201366.","journal-title":"Stroke"},{"key":"1002_CR39","unstructured":"Staerk L, Fosb\u00f8l EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C, et al. Ischaemic and haemorrhagic stroke associated with non-Vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J [Internet]. Oxford University Press; 2017;38:907\u201315. https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-85015880382&doi=10.1093%2Feurheartj%2Fehw496&partnerID=40&md5=ef5d24caa30b858dfcf6c1fa0cfbcc0d."},{"issue":"6","key":"1002_CR40","doi-asserted-by":"publisher","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","volume":"5","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.","journal-title":"J Am Heart Assoc."},{"issue":"12","key":"1002_CR41","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","volume":"49","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke. 2018;49(12):2933\u201344.","journal-title":"Stroke."},{"key":"1002_CR42","doi-asserted-by":"crossref","unstructured":"Correction to: effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke. 2020;51(4):e71.","DOI":"10.1161\/STR.0000000000000227"},{"issue":"3","key":"1002_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1160\/TH17-10-0733","volume":"118","author":"SH Hohnloser","year":"2018","unstructured":"Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non-Vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018;118(3):526\u201338.","journal-title":"Thromb Haemost."},{"key":"1002_CR44","doi-asserted-by":"crossref","unstructured":"Korenstra J, Wijtvliet EPJ, Veeger NJGM, Geluk CA, Bartels GL, Posma JL, et al. Effectiveness and safety of dabigatran versus acenocoumarol in \u201creal-world\u201d patients with atrial fibrillation. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol. 2016;18:1319\u201327.","DOI":"10.1093\/europace\/euv397"},{"key":"1002_CR45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12872-017-0672-5","volume":"17","author":"FL Norby","year":"2017","unstructured":"Norby FL, Bengtson LGS, Lutsey PL, Chen LY, MacLehose RF, Chamberlain AM, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2017;17:238.","journal-title":"BMC Cardiovasc Disord."},{"key":"1002_CR46","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1136\/bmj.i3189","volume":"353","author":"TB Larsen","year":"2016","unstructured":"Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:3189.","journal-title":"BMJ"},{"issue":"11","key":"1002_CR47","first-page":"1116","volume":"24","author":"K Gupta","year":"2018","unstructured":"Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, et al. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. department of defense population. J Manag Care Spec Pharm. 2018;24(11):1116\u201327.","journal-title":"J Manag Care Spec Pharm."},{"key":"1002_CR48","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1080\/03007995.2017.1345729","volume":"33","author":"A Amin","year":"2017","unstructured":"Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, et al. Risk of stroke\/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33:1595\u2013604.","journal-title":"Curr Med Res Opin."},{"issue":"6","key":"1002_CR49","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jjcc.2016.08.010","volume":"69","author":"LGS Bengtson","year":"2017","unstructured":"Bengtson LGS, Lutsey PL, Chen LY, MacLehose RF, Alonso A. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol. 2017;69(6):868\u201376.","journal-title":"J Cardiol."},{"issue":"2","key":"1002_CR50","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/phar.2213","volume":"39","author":"BK Martinez","year":"2019","unstructured":"Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke A-K, Eriksson D, et al. Influence of polypharmacy on the effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation. Pharmacotherapy. 2019;39(2):196\u2013203.","journal-title":"Pharmacotherapy."},{"key":"1002_CR51","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1080\/03007995.2016.1237937","volume":"32","author":"CI Coleman","year":"2016","unstructured":"Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;32:2047\u201353.","journal-title":"Curr Med Res Opin"},{"key":"1002_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.thromres.2018.05.022","volume":"167","author":"S Sj\u00e4lander","year":"2018","unstructured":"Sj\u00e4lander S, Sj\u00f6gren V, Renlund H, Norrving B, Sj\u00e4lander A. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res. 2018;167:113\u20138.","journal-title":"Thromb Res."},{"key":"1002_CR53","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11239-016-1361-4","volume":"42","author":"B Yavuz","year":"2016","unstructured":"Yavuz B, Ayturk M, Ozkan S, Ozturk M, Topaloglu C, Aksoy H, et al. A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. J Thromb Thrombolysis. 2016;42:399\u2013404.","journal-title":"J Thromb Thrombolysis"},{"key":"1002_CR54","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","volume":"61","author":"TB Larsen","year":"2013","unstructured":"Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"1002_CR55","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","volume":"30","author":"F Laliberte","year":"2014","unstructured":"Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30:1317\u201325.","journal-title":"Curr Med Res Opin"},{"key":"1002_CR56","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1016\/S2352-3026(15)00027-7","volume":"2","author":"K Bouillon","year":"2015","unstructured":"Bouillon K, Bertrand M, Maura G, Blotiere P-O, Ricordeau P, Zureik M. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study. Lancet Haematol. 2015;2:e150\u20139.","journal-title":"Lancet Haematol"},{"key":"1002_CR57","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1160\/TH15-06-0497","volume":"114","author":"JD Seeger","year":"2015","unstructured":"Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114:1277\u201389.","journal-title":"Thromb Haemost"},{"key":"1002_CR58","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","volume":"132","author":"G Maura","year":"2015","unstructured":"Maura G, Blotiere P-O, Bouillon K, Billionnet C, Ricordeau P, Alla F, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015;132:1252\u201360.","journal-title":"Circulation"},{"issue":"2","key":"1002_CR59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ehjcvp\/pvy025","volume":"5","author":"CI Coleman","year":"2019","unstructured":"Coleman CI, Turpie AGG, Bunz TJ, Eriksson D, Sood NA, Baker WL. Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. Eur Heart J Cardiovasc Pharmacother. 2019;5(2):64\u20139.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1002_CR60","doi-asserted-by":"publisher","first-page":"e0191722","DOI":"10.1371\/journal.pone.0191722","volume":"13","author":"X Li","year":"2018","unstructured":"Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS ONE. 2018;13:e0191722.","journal-title":"PLoS ONE"},{"key":"1002_CR61","doi-asserted-by":"publisher","first-page":"h1857","DOI":"10.1136\/bmj.h1857","volume":"350","author":"NS Abraham","year":"2015","unstructured":"Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.","journal-title":"BMJ"},{"key":"1002_CR62","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/1076029615584664","volume":"22","author":"LB Yap","year":"2016","unstructured":"Yap LB, Eng DTS, Sivalingam L, Rusani BI, Umadevan D, Muhammad Z, et al. A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population. Clin Appl Thromb Hemost. 2016;22:792\u20137.","journal-title":"Clin Appl Thromb Hemost."},{"key":"1002_CR63","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/dme.13648","volume":"35","author":"CI Coleman","year":"2018","unstructured":"Coleman CI, Bunz TJ, Eriksson D, Meinecke A-K, Sood NA. Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis. Diabet Med. 2018;35:1105\u201310.","journal-title":"Diabet Med."},{"key":"1002_CR64","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1160\/TH17-01-0068","volume":"117","author":"XS Li","year":"2017","unstructured":"Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \u201creal-world\u201d clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017;117:1072\u201382.","journal-title":"Thromb Haemost."},{"issue":"5","key":"1002_CR65","first-page":"975","volume":"116","author":"GYH Lip","year":"2016","unstructured":"Lip GYH, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: a propensity score matched analysis. Thromb Haemost. 2016;116(5):975\u201386.","journal-title":"Thromb Haemost."},{"key":"1002_CR66","first-page":"968","volume":"23","author":"G Adeboyeje","year":"2017","unstructured":"Adeboyeje G, Sylwestrzak G, Barron JJ, White J, Rosenberg A, Abarca J, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag care Spec Pharm. 2017;23:968\u201378.","journal-title":"J Manag care Spec Pharm."},{"key":"1002_CR67","doi-asserted-by":"crossref","unstructured":"Lee KH, Park HW, Lee N, Hyun DY, Won J, Oh SS, et al. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol. 2017;19:iv1\u20139.","DOI":"10.1093\/europace\/eux247"},{"key":"1002_CR68","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.2217\/cer-2018-0054","volume":"7","author":"S Ramagopalan","year":"2018","unstructured":"Ramagopalan S, Allan V, Saragoni S, Esposti LD, Alessandrini D, Perrone V, et al. Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. J Comp Eff Res. 2018;7:1063\u201371.","journal-title":"J Comp Eff Res"},{"key":"1002_CR69","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1060028017727290","volume":"52","author":"G Russo-Alvarez","year":"2018","unstructured":"Russo-Alvarez G, Martinez KA, Valente M, Bena J, Hu B, Luxenburg J, et al. Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting. Ann Pharmacother United States. 2018;52:19\u201325.","journal-title":"Ann Pharmacother. United States"},{"issue":"2","key":"1002_CR70","doi-asserted-by":"publisher","first-page":"e004517","DOI":"10.1161\/JAHA.116.004517","volume":"6","author":"M Lamberts","year":"2017","unstructured":"Lamberts M, Staerk L, Olesen JB, Fosb\u00f8l EL, Hansen ML, Harboe L, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. J Am Heart Assoc. 2017;6(2):e004517.","journal-title":"J Am Heart Assoc."},{"issue":"5","key":"1002_CR71","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.amjmed.2018.12.023","volume":"132","author":"DJ Graham","year":"2019","unstructured":"Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, et al. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132(5):596\u2013604.","journal-title":"Am J Med."},{"key":"1002_CR72","doi-asserted-by":"publisher","first-page":"k2505","DOI":"10.1136\/bmj.k2505","volume":"362","author":"Y Vinogradova","year":"2018","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505.","journal-title":"BMJ."},{"issue":"1","key":"1002_CR73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","volume":"3","author":"S Halvorsen","year":"2017","unstructured":"Halvorsen S, Ghanima W, Tvete IF, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3(1):28\u201336.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1002_CR74","unstructured":"S. D, A. K, X. L, M. H, C. M, K. G, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban among non-valvular atrial fibrillation patients: A propensity score matched analysis of four large databases. Circulation [Internet]. S. Deitelzweig, Dept of Hosp Medicine, Ochsner Clinic Foundation, New Orleans, LA, United States; 2017;136. http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L619986052."},{"issue":"1","key":"1002_CR75","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1038\/s41598-018-21884-y","volume":"8","author":"HY Huang","year":"2018","unstructured":"Huang HY, Lin SY, Cheng SH, Wang CC. Effectiveness and safety of different rivaroxaban dosage regimens in patients with non-valvular atrial fibrillation: a nationwide, population-based cohort study. Sci Rep. 2018;8(1):3451.","journal-title":"Sci Rep."},{"key":"1002_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejim.2016.05.023","volume":"33","author":"MH Ellis","year":"2016","unstructured":"Ellis MH, Neuman T, Bitterman H, Dotan SG, Hammerman A, Battat E, et al. Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study. Eur J Intern Med. 2016;33:55\u20139.","journal-title":"Eur J Intern Med."},{"issue":"4","key":"1002_CR77","doi-asserted-by":"publisher","first-page":"e003418","DOI":"10.1161\/CIRCOUTCOMES.116.003418","volume":"10","author":"GPS Shantha","year":"2017","unstructured":"Shantha GPS, Bhave PD, Girotra S, Hodgson-Zingman D, Mazur A, Giudici M, et al. Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2017;10(4):e003418.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"12","key":"1002_CR78","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.amjmed.2014.07.024","volume":"127","author":"MS Vaughan Sarrazin","year":"2014","unstructured":"Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, Cram P. Bleeding rates in veterans affairs patients with Atrial fibrillation who switch from Warfarin to Dabigatran. Am J Med. 2014;127(12):1179\u201385.","journal-title":"Am J Med."},{"key":"1002_CR79","unstructured":"de Jong LA, Gout-Zwart JJ, van den Bosch M, Koops M, Postma MJ. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis. J Med Econ [Internet]. 2019. https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-85060129162&doi=10.1080%2F13696998.2018.1563404&partnerID=40&md5=b196f4b9c05487232216f07a89b5fd89."},{"key":"1002_CR80","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.amjcard.2014.06.015","volume":"114","author":"A Clemens","year":"2014","unstructured":"Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, et al. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. Am J Cardiol. 2014;114:849\u201355.","journal-title":"Am J Cardiol."},{"key":"1002_CR81","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.amjcard.2015.09.048","volume":"117","author":"BM Salata","year":"2016","unstructured":"Salata BM, Hutton DW, Levine DA, Froehlich JB, Barnes GD. Cost-effectiveness of dabigatran (150 mg twice daily) and warfarin in patients >\/= 65 years with nonvalvular atrial fibrillation. Am J Cardiol. 2016;117:54\u201360.","journal-title":"Am J Cardiol."},{"key":"1002_CR82","doi-asserted-by":"publisher","first-page":"e0157129","DOI":"10.1371\/journal.pone.0157129","volume":"11","author":"X Li","year":"2016","unstructured":"Li X, Tse VC, Lau WCY, Cheung BMY, Lip GYH, Wong ICK, et al. Cost-effectiveness of apixaban versus warfarin in Chinese patients with non-valvular atrial fibrillation: a real-life and modelling analyses. PLoS ONE. 2016;11:e0157129.","journal-title":"PLoS ONE"},{"issue":"10","key":"1002_CR83","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40273-013-0087-9","volume":"31","author":"J Kleintjens","year":"2013","unstructured":"Kleintjens J, Li X, Simoens S, Thijs V, Goethals M, Rietzschel ER, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31(10):909\u201318.","journal-title":"Pharmacoeconomics."},{"issue":"6","key":"1002_CR84","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-014-0152-z","volume":"32","author":"T Wisl\u00f8ff","year":"2014","unstructured":"Wisl\u00f8ff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014;32(6):601\u201312.","journal-title":"Pharmacoeconomics."},{"key":"1002_CR85","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","volume":"131","author":"DJ Graham","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157\u201364.","journal-title":"Circulation"},{"issue":"1","key":"1002_CR86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/ehjcvp\/pvz072","volume":"7","author":"H-F Lee","year":"2021","unstructured":"Lee H-F, See L-C, Li P-R, Liu J-R, Chao T-F, Chang S-H, et al. Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. Eur Heart J Cardiovasc Pharmacother. 2021;7(1):50\u20138.","journal-title":"Eur Heart J Cardiovasc Pharmacother."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01002-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01002-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01002-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T09:02:52Z","timestamp":1674982972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01002-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01002-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"15 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Former problem: Funding information was missing and Correct information: Open access funding provided by Scuola Superiore Sant'Anna within the CRUI-CARE Agreement.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Scuola Superiore Sant'Anna within the CRUI-CARE Agreement. The study received support from Pfizer Italia and Bristol Myers Squibb Italia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data used in this study are fully available in databases.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"VL, SP and GT are employees of the Institute of Management, Scuola Superiore Sant\u2019Anna, which received financial support from Pfizer and Bristol Myers Squibb in connection with the development of this article. The authors have no other conflicts of interest to declare.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"VL conceived the paper and performed the analysis. SP performed the literature search, all the authors were involved in the systematic literature review. All authors were involved in the study design, discussion and interpretation of the results. All authors repeatedly edited the manuscript and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}